GVHD lethality and TNF-α production are reduced in IL-33-deficient recipients, and IL-33 administration during peak inflammatory response worsened GVHD in an allogeneic-hematopoietic cell transplantation model [273]. The gene discussed is IL33; the disease is graft versus host disease.